Related Experiment Video
Updated: Jun 10, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Neuroinflammatory processes in Alzheimer's disease
Michael T Heneka1, M Kerry O'Banion, Dick Terwel
1Department of Neurology, Clinical Neurosciences, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. michael.heneka@ukb.uni-bonn.de
Journal of Neural Transmission (Vienna, Austria : 1996)
|July 16, 2010
Summary
Alzheimer's disease (AD) involves amyloid plaques and tangles. Emerging evidence highlights inflammation as a key driver, potentially creating a vicious cycle with neurodegeneration. Anti-inflammatory drugs may offer protection against AD.
Area of Science:
- Neuroscience
- Pathology
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by amyloid beta peptides and neurofibrillary tangles.
- Neuroinflammation is increasingly recognized as a critical factor in AD pathogenesis.
- Degeneration of aminergic nuclei may influence brain inflammation levels.
Purpose of the Study:
- To explore the role of neuroinflammation in Alzheimer's disease progression.
- To investigate the potential of anti-inflammatory strategies for AD treatment.
- To elucidate mechanisms linking inflammation to amyloid precursor protein processing.
Main Methods:
- Review of existing evidence on neuroinflammatory mediators in AD.
- Analysis of studies on aminergic nuclei degeneration and inflammation.
- Examination of experimental data on inflammatory mediators and amyloid precursor protein (APP) processing.
- Evaluation of epidemiological data on non-steroidal anti-inflammatory drug (NSAID) use and AD risk.
Main Results:
- Neuroinflammatory mediators are actively expressed and released by various brain cells in AD.
- Inflammatory mediators can stimulate amyloid precursor protein processing, forming a vicious cycle.
- Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with reduced risk and delayed onset of AD.
Conclusions:
- Neuroinflammation is a significant component of Alzheimer's disease, potentially driving progression.
- Targeting inflammation with anti-inflammatory treatments is a promising therapeutic avenue for AD.
- Mechanisms like cyclooxygenase 2 or gamma-secretase inhibition may underlie NSAID-mediated protection in AD.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...